Thank you and good afternoon. On my behalf as well, we have once again delivered a strong quarter. Our net sales growth accelerated and also profitability improved during Q2. This was driven by Nubeqa royalties and product sales. And also our branded products division had an excellent quarter, and in research and development. We reached several key milestones, especially with ODM-212, and I will discuss that molecule later on in more detail. In Q2, our net sales increased by 25%, totaling €522 million, and operating profit increased by 69%, resulting in a 34% operating profit margin of €177 million, and earnings per share was €1.00. And of course, in our net sales development, Innovative Medicines was the main driver with €95 million. But also, when we look at Branded Products and the size of the Branded Products division, 10.3 million is a significant growth rate. All the other businesses were more or less on par. And on operating profit, the volume increased our profit by 17.3 million euros. The volume growth increased our profit by €17.3 million. Again, royalties played a key role here, contributing close to €77 million. We. We have also finalized the liquidation of our Russian operations, and the cost of that. The final cost of that liquidation, €3.3 million, is included here in other expenses, and fixed costs of €50 million are according to our plan. As we widen and progress our research and development pipeline, we continue to accelerate our sales. Part of this increase in sales and marketing costs is due to higher royalties paid to Bayer, as Nubeqa sales continue to perform well. And now, I will move to the first half of this year, from January to June. We see very similar figures here. Growth increased by 22%, totaling €939 million in net sales during the first six months, with almost 60% growth in operating profit, up to €291 million, an operating profit margin of 31%, and earnings per share of €1.64. Innovative medicines are clearly the driver for the growth. Here we can see Q2 numbers on the left and then the first half in the middle. It is really more than 60% growth both in the second quarter and during the first six months. Royalties are playing the biggest role, followed by a smaller share of other services to our partners. And I think the most important message here is on the right-side figure with the columns on different quarters, where we can once again underline the dynamics of the Nubeqa royalty income growth for Orion. It is very back-end loaded during one financial year. If you look here at Q1 2026 and compare it to the previous quarter. Q2 saw a significant increase in royalties, but also in tablet deliveries to Bayer. I think we also previously stated that the tablet deliveries may vary between the quarters. And this time there were a lot of deliveries from Orion to Bayer. Branded products. Q2 was strong, as I mentioned, almost 13% growth compared to the previous year's Q2. The biggest percentage increase was in women's health with our Divina product range, mainly Divigel, which is an estradiol gel for hormone replacement therapy. Easyhaler franchise grew 7% and Arthro. The combination product, Budesonide Formoterol, contributed mainly to that growth, while CNS was actually decreasing. Net sales decreased slightly due to price changes or price decreases in some of our global markets. Generics and consumer health were on par compared to the previous year's second quarter and also to the previous first half. First half of the previous year. The decline, a very slight decline here, comes from the generic prescription drugs, as the consumer health products are actually growing with a healthy percentage. I cannot resist saying here that if we were to exclude Simdax and Dexdor from this portfolio and look purely at our generic portfolio, not including legacy products. The generic business growth was 2%, a very healthy growth percentage for a generic business in Europe. We also entered into a license agreement for European rights to a new Nivolumab biosimilar with Shilpa, a partner with whom we are already developing products, and we are expecting to launch this new biosimilar in the 2030s. Animal Health had a tougher quarter in Q2, but let us remember that the previous year's Q2 was, if not an all-time high, exceptionally high. So the comparison period was tough. And it's always a question of deliveries to our partners in this business. And when you look at the first half of this year compared to the previous one, it is down 2.4%. And we are expecting the growth to accelerate towards the latter part of the year. We also received very good news, an approval by the FDA for a new product called Tessie. The molecule is Tasipimidine. It is an oral solution for anxiety and fear in dogs, especially if they go to strange places or need to experience new conditions. And we expect our partner to start commercial sales in mid-2027. And Fermion. External sales saw almost 20% growth in Q2 and 17% during the first half of the year. Here, the delivery timing is everything. So these are big quantities that we sell to our business-to-business customers. So we can clearly see that the first half of this year has been very busy on that front.
I am sharing this since there has been news in Finnish by the Finnish Broadcasting Company that there was water damage at one of the Fermion plants in Hanko last week during the summer maintenance period. We are fully recovering from that water damage. All the activities are being implemented as we speak. Based on our current understanding, this will not have a material effect or impact on Orion, nor will it cause any disruption to the continuity of our key products. Our top ten product list tells the same story as the therapy areas or the divisions. I am not going to go through the products in detail, but I think the key message on this slide is clearly that now, already in Q2, Innovative Medicines is the biggest division in Orion, with Generics being the second biggest and Branded Products the third biggest division. Our clinical development pipeline has remained consistent with the previous Q1 report. No new projects have been included, and no new stages have been entered. We already reported last time that we had started the combination study with our inhibitor ODM-212. And now most of the readouts for these studies are actually in 2027 or 2028, like for Nubeqa studies and opevesostat studies. But we are expecting the LEV-10 study to be read out during the latter part of this year. I have already mentioned ODM-212. Let's look at it in more detail. Let's look at that molecule in a bit more detail. So ODM-212 is a TEAD inhibitor, and we develop it for certain cancers. It has two different mechanisms that we can use for the benefit of cancer patients. The first has to do with the Hippo pathway, and some cancers are driven by it. The tumor growth is driven by this Hippo pathway. So with this inhibitor, which binds to the TEAD transcription factors, we can actually limit the growth of the tumor in these certain cancers. And currently we are studying malignant pleural mesothelioma and epithelioid hemangioendothelioma. These are very rare cancers for which there is no specific treatment currently available. So if we can find a solution for patients, it would be really great. And based on our phase one results, we strongly believe so. The other part of the story for a TEAD inhibitor is that it can also prevent resistance. Resistance to some currently used cancer medication is prevented, because it also limits some of the mechanisms that cells can develop to circumvent treatment. For example, immune checkpoint inhibitors, chemotherapy, or KRAS inhibitors. And here we talk about different cancer types like pancreatic cancer, non-small cell lung cancer (NSCLC), and also mesothelioma. So there are two ways to use this TEAD inhibitor: specifically for a certain cancer that is driven by this Hippo pathway, or to prevent resistance to currently used cancer medication. So far, we have carried out a phase one study as a monotherapy using only ODM-212, and we have seen very promising results on the efficacy. Of course, those are very early signals in mesothelioma and EHE. And we have also seen a very good side effect profile. We know that in oncology, sometimes even a bit rougher side effect profile is accepted. But here we really can see that it's very well tolerated. And based on these results, which we actually announced at ASCO this year, we started a phase two study for mesothelioma and EHE. This study is currently ongoing and expected to read out in late 2027. Based on this monotherapy study with ODM-212, we also initiated a combination study with some of the usually used drugs, such as the ones that I already mentioned for pancreatic cancer, non-small cell lung cancer, and mesothelioma. And as we think that we have a potentially best-in-class TEAD inhibitor in our hands, we also believe that if this study is successful, we can solve many problems that are related to the resistance of current medication. And this could become a drug of choice to be combined with those medications. We also received orphan drug designation in the U.S. and Europe for mesothelioma and EHE. And that, of course, validates our belief that this is a very important study and an important drug for patients. We are currently eagerly awaiting the combination study results. The study is a Phase 1b/2 study. As we are also trying to find a suitable dosing for these combination studies before we go seamlessly into phase two. So these studies' readout is in 2029. Now to a very different topic: sustainability. Orion was listed, I think for the fifth or sixth time now, as one of Europe's Climate Leaders by the Financial Times this year. And I think this graph speaks for itself. As you can see, our emissions have decreased year by year. We started the program many years ago, and in 2019, we switched fully to clean, carbon-free electricity. And we have also carried out many different activities to reach our goal. We changed from crude oil in our steam production first to gas, then electricity. We have local heat stations on our campuses where we use the heat recovered from our manufacturing facilities for the whole campus. We are also carrying out many different types of renovations to be as carbon neutral as possible. We also understand that there is a way to go. And finally, I think the last piece of the emissions will be compensated in the end.
And today we specified our outlook for this year. This is another strong quarter. So we thought that this is the place to do it. So we actually raised the lower range of our outlook by 50 million. So now the range for net sales is from 2 billion to 2.1 billion. And the range for our operating profit is from 650 million to 750 million. And here you can see our upcoming events. Next time we will be reporting in late October, and then the full-year report of 2026 will be in the middle of February.
I thank you for your attention.